“We believe that the approval of Alecensa by the TFDA would bring the great news to Taiwanese patients who are fighting against this disease,” said Dr. Yasushi Ito, Chugai’s Senior Vice President, Head of Project & Lifecycle Management Unit. “We are pleased that Alecensa created by Chugai will contribute to the treatment of ALK-positive NSCLC.”
Category: The Data Company
View Press Release
A Once-Daily Treatment that Demonstrated Comparable Efficacy with Improved Renal and Bone Laboratory Safety Parameters Compared to Tenofovir Disoproxil Fumarate — )–Gilead Sciences, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved Vemlidy 25mg, a once-daily treatment for suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function. Vemlidy is a novel targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of tenofovir disoproxil fumarate 300mg.